Organon (OGN) Total Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Current Liabilities of $2.5 billion for Q1 2026, down 4.4% year-over-year from $2.6 billion in Q1 2025, and up 4.6% on a QoQ basis from $2.4 billion in Q4 2025.
Organon (OGN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Total Current Liabilities for 7 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 4.4% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (down 4.4% YoY), while the FY2025 annual figure was $2.4 billion, down 12.07% from the prior year.
- Total Current Liabilities came in at $2.5 billion for Q1 2026 at Organon, up from $2.4 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $2.9 billion in Q4 2023, with the low at $2.3 billion in Q1 2022.
- Average Total Current Liabilities over 5 years is $2.6 billion, with a median of $2.5 billion recorded in 2022.
- Across the five-year window, Total Current Liabilities slipped 25.6% in 2022 and gained 16.16% in 2023, its largest moves.
- Year by year, Total Current Liabilities stood at $2.5 billion in 2022, then grew by 16.16% to $2.9 billion in 2023, then dropped by 6.85% to $2.7 billion in 2024, then retreated by 12.07% to $2.4 billion in 2025, then gained by 4.6% to $2.5 billion in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.5 billion, $2.4 billion, and $2.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 2.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Bn |
| Dec 31, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.68 Bn |
| Jun 30, 2025 | 2.80 Bn |
| Mar 31, 2025 | 2.62 Bn |
| Dec 31, 2024 | 2.72 Bn |
| Sep 30, 2024 | 2.79 Bn |
| Jun 30, 2024 | 2.76 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 2.92 Bn |
| Sep 30, 2023 | 2.49 Bn |
| Jun 30, 2023 | 2.39 Bn |
| Mar 31, 2023 | 2.35 Bn |
| Dec 31, 2022 | 2.51 Bn |
| Sep 30, 2022 | 2.33 Bn |
| Jun 30, 2022 | 2.40 Bn |
| Mar 31, 2022 | 2.31 Bn |
| Dec 31, 2021 | 2.60 Bn |
| Sep 30, 2021 | 3.13 Bn |
| Jun 30, 2021 | 2.98 Bn |